https://www.nasdaq.com/press-release/amphastar-receives-fda-tentative-approval-for-vasopressin-2021-12-29
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-piper-sandler-33rd-annual-virtual
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-2
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-1
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-2021-virtual-healthcare
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-raymond-james-human-health-innovation
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference-0
https://www.nasdaq.com/press-release/amphastar-announces-buyback-of-26-of-the-equity-in-its-anp-subsidiary-and-spin-off
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-1
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-receives-fda-approval-for-morphine-sulfate-injection-2021
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-20th-annual-needham-virtual-healthcare
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-receives-fda-approval-for-dextrose-injection-2021-03-29
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-raymond-james-2021-institutional
https://www.nasdaq.com/press-release/amphastar-announces-approval-for-glucagon-for-injection-kit-1mg-2020-12-29
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-0
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-receives-fda-approval-for-atropine-sulfate-injection-2020
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-wells-fargo-2020-virtual-healthcare
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-june
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-second-quarter-earnings-and-hold-conference-call
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-bmo-prescriptions-for-success-healthcare
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-raymond-james-virtual-2020-human
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-inc.-receives-fda-approval-for-succinylcholine-chloride
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-jefferies-virtual-healthcare-conference
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended-march
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-first-quarter-earnings-and-hold-conference-call
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-inc.-receives-fda-approval-for-epinephrine-injection-usp
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-inc.-announces-simplification-of-management-structure-2020
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-19th-annual-needham-virtual-healthcare
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-and-full
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-fourth-quarter-earnings-and-hold-conference-call
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-receives-fda-approval-for-supplement-to-its-abbreviated-new
https://www.nasdaq.com/press-release/amphastar-announces-the-receipt-of-a-minor-crl-for-epinephrine-injection-usp-30mg
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-31st-annual-piper-jaffray-healthcare
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-present-at-the-jefferies-london-healthcare-conference
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-reports-financial-results-for-the-three-months-ended
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-to-release-third-quarter-earnings-and-hold-conference-call
https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-release-fourth-quarter-earnings-and-hold-conference-call
